Bipolar Disorder:

An Update

Log in or subscribe to view full content.
Article is also available for purchase the article in one of the available formats.
Rif S. El-Mallakh, MD; Ahmed Z. Elmaadawi, MD; Muruga Loganathan, MD; Kavita Lohano, MD; and Yonglin Gao, MD

Table of Contents

Postgraduate Medicine:

Volume 122 No. 4


Clinical Focus

Purchase this article in one of the formats specified below:

DOI: 10.3810/pgm.2010.07.2172
Abstract: There has been a recent increase in the number of clinical trials and treatment options for bipolar disorder. This research has resulted in new treatment options. Most second-generation antipsychotics have demonstrated efficacy in the treatment of mania, both in monotherapy and as adjuncts to mood stabilizers. For bipolar depression, nearly all randomized, placebo-controlled studies have demonstrated that antidepressants do not provide any additional benefit to ongoing mood stabilizers. Additionally, antidepressants carry a risk of destabilization of bipolar disorder with an increase in mania, cycling, and chronic irritable dysphoria. Newer non-antidepressant treatments for depression include quetiapine, lamotrigine, modafinil, and pramipexole. These agents are effective for acute treatment and appear to be effective in maintenance. The least-studied phase of bipolar disorder is the maintenance phase. The use of multiple agents appears to be superior to monotherapy in relapse prevention. Despite the many advances in the pharmacotherapy of bipolar disorder, the overall prognosis of this severe illness does not appear to have changed.

Keywords: bipolar disorder , quetiapine , lamotrigine , modafinil , pramipexole